TY - JOUR
T1 - SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival
AU - de Vries, Lisa H.
AU - Lodewijk, Lutske
AU - Willems, Stefan M.
AU - Dreijerink, Koen M.A.
AU - de Keizer, Bart
AU - van Diest, Paul J.
AU - Schepers, Abbey
AU - Bonenkamp, Han J.
AU - van Engen-van Grunsven, Ilse A.C.H.
AU - Kruijff, Schelto
AU - van Hemel, Bettien M.
AU - Links, Thera P.
AU - Nieveen van Dijkum, Els J.M.
AU - van Eeden, Susanne
AU - Valk, Gerlof D.
AU - Borel Rinkes, Inne H.M.
AU - Vriens, Menno R.
N1 - Funding Information:
We are grateful to Hans Morreau for his time to select the medullary thyroid carcinoma tissue of the LUMC. We would like to thank Domenico Castiliego for his contribution in the construction of the TMA. The authors declare that they have no conflict of interest.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018
Y1 - 2018
N2 - Purpose: Medullary thyroid carcinoma (MTC) derives from the parafollicular C-cells of the thyroid gland. Somatostatin receptors (SSTRs) are expressed in various neuroendocrine tumours including MTC. The aim of this study was to evaluate SSTR2A as a prognostic factor for MTC, to study distribution of SSTR2A expression within tumours and to compare expression of SSTR2A between primary tumours and corresponding lymph node metastases. Methods: Patients who underwent surgery between 1988 and 2014 for MTC from five tertiary referral centres in The Netherlands were included. In total, primary tumours of 114 patients and lymph node metastases of 34 patients were analysed for expression of SSTR2A using a tissue microarray, and correlated with clinicopathological variables and survival. Results: The mean age of patients was 45.5 years (SD 16.2), 55 patients were male (49.5%). Primary tumours of 58 patients (50.9%) showed SSTR2A expression. In multivariate Cox-regression analysis, SSTR2A positivity correlated independently with better overall survival (OS) (HR 0.3; 95% CI 0.1–1.0). In stage IV MTC patients, 10-year survival rates for SSTR2A-negative and positive patients were 43% and 96%, respectively. In 53.9% of patients with lymph node metastases, expression in primary tumour and lymph node metastases differed. Conclusion: SSTR2A expression is correlated with longer OS in MTC, especially for stage IV patients, suggesting that SSTR2A expression might be a useful prognostic factor in MTC. The SSTR2A status of the primary MTC does not predict expression in lymph node metastases.
AB - Purpose: Medullary thyroid carcinoma (MTC) derives from the parafollicular C-cells of the thyroid gland. Somatostatin receptors (SSTRs) are expressed in various neuroendocrine tumours including MTC. The aim of this study was to evaluate SSTR2A as a prognostic factor for MTC, to study distribution of SSTR2A expression within tumours and to compare expression of SSTR2A between primary tumours and corresponding lymph node metastases. Methods: Patients who underwent surgery between 1988 and 2014 for MTC from five tertiary referral centres in The Netherlands were included. In total, primary tumours of 114 patients and lymph node metastases of 34 patients were analysed for expression of SSTR2A using a tissue microarray, and correlated with clinicopathological variables and survival. Results: The mean age of patients was 45.5 years (SD 16.2), 55 patients were male (49.5%). Primary tumours of 58 patients (50.9%) showed SSTR2A expression. In multivariate Cox-regression analysis, SSTR2A positivity correlated independently with better overall survival (OS) (HR 0.3; 95% CI 0.1–1.0). In stage IV MTC patients, 10-year survival rates for SSTR2A-negative and positive patients were 43% and 96%, respectively. In 53.9% of patients with lymph node metastases, expression in primary tumour and lymph node metastases differed. Conclusion: SSTR2A expression is correlated with longer OS in MTC, especially for stage IV patients, suggesting that SSTR2A expression might be a useful prognostic factor in MTC. The SSTR2A status of the primary MTC does not predict expression in lymph node metastases.
KW - Immunohistochemistry
KW - Medullary thyroid carcinoma
KW - Oncology
KW - Somatostatin receptor 2A
KW - Tissue microarray
UR - http://www.scopus.com/inward/record.url?scp=85051834393&partnerID=8YFLogxK
U2 - 10.1007/s12020-018-1706-1
DO - 10.1007/s12020-018-1706-1
M3 - Article
AN - SCOPUS:85051834393
SN - 1355-008X
VL - 62
SP - 639
EP - 647
JO - Endocrine
JF - Endocrine
IS - 3
ER -